Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Peposertib · MSC-2490484A, M-3814

Small molecule · Inhibitor of DNA-dependent protein kinase (PRKDC) · developed by EMD Serono Research & Development Institute

Phase 1 Most advanced trial (none active)

What is Peposertib?

Peposertib is an orally bioavailable small-molecule inhibitor of DNA-dependent protein kinase (DNA-PK). It binds and inhibits DNA-PK, interfering with non-homologous end joining and blocking repair of DNA double-strand breaks caused by radiation or chemotherapy, with potential sensitizing effects on those treatments.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MSC-2490484A, M-3814
Drug type
Small molecule
Targets
DNA-dependent protein kinase (PRKDC)
Mechanism
Inhibitor of DNA-dependent protein kinase (PRKDC)
Pathways
non-homologous end joining (NHEJ) DNA double-strand break repair
Developer
EMD Serono Research & Development Institute, Inc.
In trials of
MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
GN429E725A

Conditions studied

Healthy

Other drugs acting on PRKDC

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.